Stock 002399 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
8.73 CNY -2.68% Intraday chart for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. -3.54% -25.58%
29/04 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02/04 Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane MT

Business Summary

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Number of employees: 2,080

Sales per Business

CNY in Million2022Weight2023Weight Delta
Preparation
54.7 %
3,210 44.8 % 2,979 54.7 % -7.21%
API
24.0 %
2,674 37.3 % 1,308 24.0 % -51.09%
Contract Development and Manufacturing Operations
17.8 %
1,084 15.1 % 967 17.8 % -10.80%
Others
3.5 %
191 2.7 % 192 3.5 % +0.35%

Sales per region

CNY in Million2022Weight2023Weight Delta
Europe
48.0 %
3,730 52.1 % 2,616 48.0 % -29.87%
United States
23.5 %
1,387 19.4 % 1,278 23.5 % -7.90%
Other Countries
20.6 %
1,290 18.0 % 1,122 20.6 % -13.01%
China
7.6 %
643 9.0 % 412 7.6 % -35.83%
Hong Kong
0.3 %
103 1.4 % 18 0.3 % -82.43%

Managers

Managers TitleAgeSince
Yu Shan FOU
 Founder 64 21/98/21
Tan Li FOU
 Founder 60 21/98/21
Juan Chen DFI
 Director of Finance/CFO 49 21/23/21
Ming Jie Wu CTO
 Chief Tech/Sci/R&D Officer - -
Ji Lan Su BRD
 Director/Board Member 45 01/04/01
Wen Xuan Zhang IRC
 Investor Relations Contact 35 -
Tao Han PRN
 Corporate Officer/Principal - -
Feng Qi Qian SEC
 Corporate Secretary 39 01/21/01

Members of the board

Members of the board TitleAgeSince
Tan Li FOU
 Founder 60 21/98/21
Peng Huang BRD
 Director/Board Member 75 22/23/22
Li Li FOU
 Founder 60 21/98/21
Yu Shan FOU
 Founder 64 21/98/21
Hai Jun Tang BRD
 Director/Board Member 46 01/01/01
Ji Lan Su BRD
 Director/Board Member 45 01/04/01
Ze Hui Zheng CHM
 Chairman 54 16/14/16
Chu An Lü BRD
 Director/Board Member 54 18/19/18
Ming Yi BRD
 Director/Board Member 47 22/23/22
Ping Zhang BRD
 Director/Board Member 59 22/23/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 220,094,500 0 0 17.01 %
Stock B 1 1,247,201,704 249,584,561 ( 20.01 %) 0

Shareholders

NameEquities%Valuation
Zejun Hong
6.016 %
13,240,000 6.016 % 6 M ¥
AVIC Trust Co., Ltd.
5.738 %
12,629,500 5.738 % 6 M ¥
OrbiMed Advisors Private Equity
4.832 %
10,634,500 4.832 % 5 M ¥
State Street Global Advisors Ltd.
0.0507 %
111,513 0.0507 % 50 887 ¥
Bosera Asset Management Co., Ltd.
0.0382 %
84,000 0.0382 % 38 332 ¥
NameEquities%Valuation
Li Li
41.24 %
514,349,899 41.24 % 706 M ¥
Tan Li
32.72 %
408,041,280 32.72 % 560 M ¥
Yu Shan
3.722 %
46,425,600 3.722 % 64 M ¥
Shenzhen Hepalink Pharmaceutical Group Co. Ltd. ESOP
1.212 %
15,118,035 1.212 % 21 M ¥
China Asset Management Co., Ltd.
0.5022 %
6,263,192 0.5022 % 9 M ¥
China Southern Asset Management Co., Ltd.
0.2253 %
2,809,960 0.2253 % 4 M ¥
CCB Principal Asset Management Co., Ltd.
0.0921 %
1,148,733 0.0921 % 2 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.0812 %
1,012,200 0.0812 % 1 M ¥
Fullgoal Fund Management Co., Ltd.
0.0727 %
906,200 0.0727 % 1 M ¥
Great Wall Fund Management Co., Ltd.
0.0429 %
535,400 0.0429 % 735 399 ¥

Holdings

NameEquities%Valuation
RESVERLOGIX CORP.
31.03%
 85,286,524 31.03% 3,496,747 $
QUEST PHARMATECH INC.
14.78%
 25,000,000 14.78% 375,000 $
GT BIOPHARMA, INC.
4.26%
 91,860 4.26% 344,475 $

Company contact information

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

21 Langshan Road Song Ping Shan

518057, Shenzhen

+

http://www.hepalink.com
address Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(002399)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Generic Pharmaceuticals

Sales per Business

Sales per region

Ratings for Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
8.73 CNY
Average target price
6.2 CNY
Spread / Average Target
-28.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. Stock Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
-25.58% 1.59B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.39% 43.59B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+28.00% 22.54B
SANDOZ GROUP AG Stock Sandoz Group AG
+21.43% 15.73B
CIPLA LIMITED Stock Cipla Limited
+18.87% 14.33B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+56.65% 12.75B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.70% 6.48B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+15.72% 5.67B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002399 Stock
  4. Company Shenzhen Hepalink Pharmaceutical Group Co., Ltd.